Diabetes in a high secure hospital

Postgraduate Medical Journal

Volumn 80, Issue 939, 2004, Pages 35-37

  MacFarlane, I A ^a   Gill, G V ^a   Finnegan, D ^b   Pinkney, J ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b ASHWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; FLUPENTIXOL; GLICLAZIDE; HEMOGLOBIN; INSULIN; LITHIUM; METFORMIN; NEUROLEPTIC AGENT; ORAL ANTIDIABETIC AGENT; SULPIRIDE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC OBESITY; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HOSPITAL; HOSPITAL ADMISSION; HUMAN; LAW; MALE; MENTAL HEALTH; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PROSPECTIVE STUDY; SCHIZOPHRENIA; WEIGHT GAIN;

ADULT; AGED; DIABETES MELLITUS; ENGLAND; EPIDEMIOLOGIC METHODS; FEMALE; HOSPITALIZATION; HOSPITALS, SPECIAL; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED;

EID: 1242314721     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.2003.006601     Document Type: Article

References (27)

1. Ismail AA, Beeching NJ, Gill GV, et al. Capture-recapture adjusted prevalence rates of type 2 diabetes are related to social deprivation. Q J Med 1999;92:707-10.
2. Currie CJ, Kraus D, Morgan CL, et al. NHS acute sector expenditure for diabetes. The present, future, and excess in-patient costs of care. Diabet Med 1997;14:686-93.
3. Kooy FH. Hyperglycaemia in mental disorders. Brain 1919;42:214-88.
4. Lorenz WF. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 1922;8:184-96.
5. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73.
6. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia - a preliminary study. J Clin Hosp Pharm 1986;11:297-9.
7. Ackerman S, Nolan LJ. Bodyweight gain induced by psychotropic drugs. Incidence, mechanisms and management. CNS Drugs 1998;9:135-51.
8. Spoelstra JA, Stolk RP, Klungel JA, et al. Antipsychotic drugs may worsen metabolic control in type 2 diabetes. Diabetologia 2001;44(suppl 1):A60.
9. Taylor PJ. Maximum security hospitals: can we do without them? In: Hawton K, Cowen P, eds. Practical problems in clinical psychiatry. Oxford: Oxford University Press, 1992.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
11. WHO Consultation on Obesity. Preventing and managing the global epidemic. Geneva: World Health Organisation, 1997:1-276.
12. Riste L, Khan F, Cruikshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city. Diabetes Care 2001;24:1377-83.
13. Masson EA, MacFarlane IA, Power E, et al. A audit of the management and outcome of hospital inpatients with diabetes - resource planning implications for the diabetes care team. Diabetic Med 1992;9:753-5.
14. Currie CJ, Williams DRR, Peters JR. Patterns of in and outpatient activity for diabetes: a district survey. Diabetic Med 1996;13:273-80.
15. Gill GV, MacFarlane IA. Problems of diabetics in prison. BMJ 1989;298:221-3.
16. MacFarlane IA, Gill GV, Masson E, et al. Diabetes in prison; can good diabetic care be achieved? BMJ 1992;304:152-5.
17. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;45:790-7.
18. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenic samples. Schizophr Bull 2000;26:903-12.
19. Erle G, Basso M, Federspil G, et al. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacol 1977;11:15-18.
20. Brambilla F, Guastalla A, Guerrini A, et al. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst 1976;37:98-103.
21. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities - a five year naturalistic study. Am J Psychiatry 2000;157:975-81.
22. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel anti-psychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
23. Kinon BJ, Basson BR, Gilmore JA, et al. Long term olanzepine treatment: weight change and weight related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100.
24. Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical antipsychotic drugs - a report of three cases. Diabet Med 2000;17:484-6.
25. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001;11:716-23.
26. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1390-2.
27. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.